Ifedayo Adetifa/Vaccine
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.Sparrow E
Adetifa I
Chaiyakunapruk N
Cherian T
Fell DB
Graham BS
Innis B
Kaslow DC
Karron RA
Nair H
Neuzil KM
Saha S
Smith PG
Srikantiah P
Were F
Zar HJ
Feikin D
Vaccine, (2022). 40:3506-3510
Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.Ojal J
Flasche S
Hammitt LL
Akech D
Kiti MC
Kamau T
Adetifa I
Nurhonen M
Scott JAG
Auranen K
Vaccine, (2017). 35:4561-4568
